31 results
8-K
COGT
Cogent Biosciences Inc
25 Jul 19
Departure of Directors or Certain Officers
4:47pm
restrictive covenants, including an inventions assignment, retention agreement, and confidentiality agreement.
SIGNATURES
Pursuant to the requirements
PRE 14A
COGT
Cogent Biosciences Inc
7 Feb 20
Preliminary proxy
5:28pm
are ineffective at providing the incentives and retention value that our Board of Directors believes are necessary to motivate our management and our … .
Consideration of Alternatives
Our compensation committee considered alternatives to the Option Exchange to provide meaningful performance and retention
SC TO-I
EX-99
COGT
Cogent Biosciences Inc
8 Apr 20
Issuer tender offer statement
5:13pm
the incentives and retention value that our Board of Directors believes are necessary to motivate our management and our employees to achieve our strategic … , these options are ineffective at providing the incentives and retention value that our Board believes are necessary to motivate our management and our
DEF 14A
o5eg1cw s5fdhiu9m5z
30 Apr 19
Definitive proxy
5:25pm
8-K
EX-10.1
7s9m 1lsxr8cltt3hui
14 Feb 24
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
8:35am
8-K
EX-2.1
cr4d44 pf
6 Jul 20
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
10:31am
DEFM14A
7rz8wy9lx965lc2b6
9 Oct 20
Proxy related to merger
4:44pm
8-K
EX-1.1
jxj8rnullleo5sgu
2 Dec 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-1.1
to0r1 3m4htmlg3ljy
8 Jun 23
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-1.1
2px5g1l
15 Jun 22
Entry into a Material Definitive Agreement
5:18pm
8-K/A
EX-1.1
5adou
16 Jun 22
Entry into a Material Definitive Agreement
5:03pm